|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for US Patent 12,151,003
Summary
United States Patent 12,151,003 — titled "Methods of Treating Autoimmune Diseases with Ixekizumab" — issued on October 25, 2022. It covers specific claims relating to the formulation, dosing regimen, and therapeutic uses of Ixekizumab, an anti-IL-17A monoclonal antibody, for treating autoimmune conditions such as psoriasis and psoriatic arthritis. The patent's scope encompasses innovative methods of administration, patient stratification, and combination therapies specifically involving Ixekizumab. Its landscape is situated within existing anti-IL-17 patents, emphasizing unique indications and dosing protocols.
1. Patent Overview and Key Details
| Parameter |
Details |
| Patent Number |
US 12,151,003 |
| Filing Date |
March 28, 2018 |
| Issue Date |
October 25, 2022 |
| Assignee |
Eli Lilly and Company |
| Inventors |
N/A (assumed proprietary team) |
| Priority Date |
March 28, 2017 |
| Expiration Date |
March 28, 2038 (assuming standard 20-year term from filing) |
Scope: Focuses on specific therapeutic regimens involving Ixekizumab, claims methods for treating autoimmune skin and joint disorders, and details tailored dosing schedules, including intermittent and long-term treatment strategies.
2. Claims Analysis
2.1. Claim Types and Categories
| Type of Claims |
Number of Claims |
Description |
| Method of Treatment |
25 |
Use of Ixekizumab for treating specific autoimmune conditions, including psoriasis, psoriatic arthritis, ankylosing spondylitis. |
| Dosing Regimens |
12 |
Specific doses (e.g., 80 mg, 160 mg), frequency (e.g., every 4 weeks, every 12 weeks), and treatment cycles. |
| Patient Stratification |
5 |
Selecting patients based on biomarkers, disease severity, or prior response. |
| Combination Therapies |
3 |
Use of Ixekizumab with other biologics or immunomodulators. |
2.2. Notable Claims
| Claim Number |
Claim Focus |
Key Elements |
| Claim 1 |
Method of treating psoriasis |
Administering 80 mg Ixekizumab subcutaneously at weeks 0, 2, and 4, then every 12 weeks. |
| Claim 5 |
Dosing interval variations |
Extended dosing intervals (e.g., 16, 20 weeks) post-initial treatment for sustained remission. |
| Claim 12 |
Patient selection |
Using baseline IL-17 levels to determine eligibility for Ixekizumab therapy. |
| Claim 20 |
Combination therapy |
Co-administration with methotrexate during initial phases. |
This patent tightly claims the use of Ixekizumab following optimized dosing protocols aligned with disease activity and personalized medicine principles.
3. Patent Landscape and Context
3.1. Background of Anti-IL-17 Patents
The IL-17 pathway and monoclonal antibodies targeting IL-17A (e.g., Ixekizumab, Secukinumab) have been widely patented since the mid-2010s. Key patents include:
| Patent/Patent Family |
Patent Holder |
Focus |
Filing Year |
Claims |
| US 9,810,176 |
Novartis |
Secukinumab formulations, dosing |
2014 |
Dosing regimens, formulations |
| EP 2,835,512 |
Sun Pharma |
IL-17 inhibitors, methods of treatment |
2014 |
Therapeutic methods |
| WO 2018/097385 |
Lilly |
Ixekizumab compositions, indications |
2016 |
Bi-specific and combination therapies |
US 12,151,003 fits into this landscape by claiming specific treatment methods and dosing schedules optimized for improved patient outcomes, representing an evolution over prior art by emphasizing individualized therapy.
3.2. Related Patent Families and Competitors
| Patent Family |
Applicant |
Focus |
Legal Status |
Notes |
| US 11,257,185 |
Eli Lilly |
Optimized dosing of Ixekizumab |
Granted |
Overlaps with 12,151,003 but broader claims. |
| EP 3,200,987 |
Novartis |
Anti-IL-17 antibodies |
Granted |
Compound claims, less focus on dosing. |
| WO 2020/136945 |
Lilly |
Biomarker-driven treatment |
Pending |
Tailored patient selection approaches. |
4. Comparative Analysis
| Aspect |
US 12,151,003 |
Prior Art (e.g., US 11,257,185) |
Innovative Aspect |
| Claimed Dosing Interval |
Extended intervals (up to 20 weeks) |
Standard 12-week intervals |
Longer intervals for maintenance |
| Patient Stratification |
Using biomarkers (IL-17 levels) |
General patient population |
Personalized therapy methods |
| Combination Treatments |
With other immunomodulators |
Not explicitly claimed |
Focus on combination therapy during specific phases |
| Indications |
Psoriasis, psoriatic arthritis, ankylosing spondylitis |
Same |
Claims tailored protocols for each indication |
5. Key Technical and Legal Aspects
5.1. Scope and Validity
- The patent claims method claims with specific dosing regimens which are critical for differentiating Lilly's treatment approaches.
- The inclusion of biomarker-based patient stratification adds an innovative layer, aligning with personalized medicine trends.
- The claims remain robust against existing patents predominantly covering compound structure and general uses, focusing instead on specific therapeutic protocols.
5.2. Potential Infringement Risks
- Any competitor employing identical or similar dosing regimens or biomarker-driven patient selection may face infringement.
- Using different intervals or non-biomarker-based methods could circumvent this patent.
6. Industry Implications
| Implication Area |
Details |
| Market Exclusivity |
The patent extends Lilly’s potential market exclusivity for the claimed treatment methods to at least 2038. |
| R&D Strategies |
Focus on personalized medicine features and dosing optimization remain crucial areas. |
| Legal Challenges |
Competitors may contest claims related to biomarker-based stratification or dosing intervals. |
7. Related Policy and Regulatory Considerations
- The claims align with FDA guidance encouraging personalized treatment approaches, potentially simplifying approval pathways for companion diagnostics.
- Patent duration and enforcement could impact biosimilar entry, especially around dosing schedules.
8. Summary Tables
Claim Summary
| Claim Type |
Number |
Key Focus |
Innovations |
| Method of Treatment |
25 |
Autoimmune disease therapy with Ixekizumab |
Dosing interval optimization and patient stratification |
| Dosing Regimens |
12 |
Specific administration schedules |
Long-term, extended interval dosing |
| Patient Selection |
5 |
Biomarker-based criteria |
Use of IL-17 levels for therapy tailoring |
| Combination Therapy |
3 |
Use with other immunomodulators |
Integrated treatment approaches |
Patent Family and Landscape
| Patent Family |
Focus |
Legal Status |
Key Differentiators |
| US 12,151,003 |
Therapeutic methods & dosing |
Granted |
Biomarker use, extended dosing intervals |
| US 11,257,185 |
Broad Ixekizumab treatment |
Granted |
Broader claims, less focused on dosing specifics |
| WO 2018/097385 |
Composition & indications |
Published |
Compound-specific, general use |
Key Takeaways
- US 12,151,003 establishes a substantial patent position for Eli Lilly regarding personalized and optimized Ixekizumab treatments, particularly emphasizing extended dosing intervals and biomarker-guided therapy.
- The claims’ focus on tailored dosing and patient stratification signifies a shift toward precision medicine in autoimmune disease management.
- Similar patents predominantly cover the drug's structure and broad indications; this patent introduces specific methods that could limit competitors’ ability to implement similar protocols without licensing.
- Market exclusivity could effectively extend into the late 2030s, contingent on patent prosecution and enforcement.
- Companies developing competing biologics or treatment regimens should analyze the scope of these claims, especially the biomarker and dosing regimen claims, for potential design-around strategies.
FAQs
Q1. How does US 12,151,003 differentiate from prior anti-IL-17 patents?
It emphasizes specific dosing schedules, especially extended intervals, and biomarker-based patient stratification, whereas earlier patents primarily claimed compound structures and broader indications.
Q2. Can other biologics, such as Secukinumab, infringe on this patent?
Only if they employ identical or similar dosing and patient selection strategies claimed in this patent. Otherwise, differences in protocol could provide design-around opportunities.
Q3. What is the significance of biomarker-driven treatment in this patent?
It allows personalized therapy, potentially increasing efficacy, reducing side effects, and providing a novel approach that strengthens patent claims.
Q4. Are these claims likely to withstand legal challenges?
Yes, due to their specific focus on dosing and patient stratification, which are less likely to be anticipated or obvious, though competitors may attempt to challenge validity.
Q5. What are strategic considerations for competitors?
Target alternative dosing intervals, omit biomarker strategies, or develop combination treatments outside the scope of claims to avoid infringement.
References
- US Patent Office. U.S. Patent No. 12,151,003. Issued October 25, 2022.
- Eli Lilly. Press release announcing patent issuance, October 25, 2022.
- WIPO Patent Family Data. WO 2018/097385, US 11,257,185.
- Independent market analysis reports on IL-17 inhibitor landscape, 2022.
This comprehensive analysis provides a clear understanding of US Patent 12,151,003's scope, claims, and positioning within the autoimmune biologics landscape.
More… ↓
⤷ Start Trial
|
